Article Figures & Data
Figures
- Figure 1.
bDMARD cost and usage from June 1, 2014, to June 1, 2018. (A) Total medication cost of patients being treated with bDMARDs. (B) Average cost per patient being treated with bDMARDs. bDMARD: biologic disease-modifying antirheumatic drug.
- Figure 1.
(C) The percentage of patients who were bDMARD users. bDMARD: biologic disease-modifying antirheumatic drug.
Tables
- Table 1.
Patient characteristics of the total population and the subgroup of patients using bDMARDs on June 1, 2016.
RA Population, n = 827 bDMARD Users, n = 141 Values n Values n Age, yrs, mean (SD) 63 (14) 827 58 (14) 141 Disease duration, yrs, mean (SD) 8 (8) 824 11 (9) 141 Female sex, % 65 541 70 99 DAS28, mean (SD) 3.1 (1.2) 630 3.3 3.3 (1.5) RF positive, % 57 392/683 56 69/123 Anti-CCP positive, % 55 378/684 63 78/123 BMI, kg/m2, mean (SD) 27 (10) 432 26 (5) 58 Anti-CCP: anticyclic citrullinated peptide antibody; bDMARD: biologic disease-modifying antirheumatic drug; DAS28: Disease Activity Score in 28 joints; RA: rheumatoid arthritis; RF: rheumatoid factor.
- Table 2.
Patient characteristics and medication use of patients starting biologic treatment in the years 2015 and 2017.
Before Introduction of Biosimilar, n = 59 After Introduction of Biosimilar, n = 67 N N Baseline characteristics Mean (SD) age at biologic initiation, yrs 52 (14) 59 58 (14) 67 Mean (SD) disease duration at biologic initiation, yrs 4 (6) 59 4 (6) 67 Female sex, % 74.6 44 70.1 47 RF positive, % 42.3 22/52 56.4 22/39 Anti-CCP positive, % 51.9 27/52 55.6 25/45 BMI, mean (SD) 27.0 (7) 40 27.8 (7) 35 DAS28 at biologic initiation, mean (SD) 4.7 (1.3) 38 4.5 (1.2) 42 Medication use prior to initiation of first bDMARD No. csDMARDs used, mean (SD) 2.1 (0.7) 57 2.1 (0.7) 60 Patients with GC treatment in last year, % 73 43 73 49 No. prednisone prescriptions in last year, mean (SD) 2.7 (2.5) 59 2.6 (2.6) 67 Medication use during initiation of first bDMARD Distribution of bDMARD utilization at initiation of first bDMARD Abatacept – – 2 1 Adalimumab 53 31 42 28 Etanercept 36 21 46 31 Certolizumab – – 3 2 Golimumab 3 2 2 1 Infliximab 2 1 – – Rituximab 5 3 3 2 Tocilizumab 2 1 3 2 No. csDMARD at biologic initiation (co-medication) 0 14 8 27 18 1 44 26 37 25 2 42 25 35 24 Patients using MTX at biologic initiation, % 68 40 54 36 Anti-CCP: anticyclic citrullinated peptide antibody; bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28: Disease Activity Score in 28 joints; GC: glucocorticoid; MTX: methotrexate; RF: rheumatoid factor.
